FOXD2 and neoplasm: Recently, a study demonstrated that overexpression of FOXD2-AS1 was associated with poor clinical outcomes in PTC patients, and the knockdown of FOXD2-AS1 could suppress tumor growth by reversing its sponge effect (56).